Get the Stockscreener App
47.86
0.50%
0.24
After Hours:
47.54
-0.32
-0.67%
Sanofi Adr stock is traded at $47.86, with a volume of 5.61M.
It is up +0.50% in the last 24 hours and down -9.51% over the past month.
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
See More
Previous Close:
$47.62
Open:
$48.07
24h Volume:
5.61M
Relative Volume:
2.15
Market Cap:
$121.02B
Revenue:
$48.62B
Net Income/Loss:
$6.80B
P/E Ratio:
17.07
EPS:
2.8038
Net Cash Flow:
$7.62B
1W Performance:
-3.64%
1M Performance:
-9.51%
6M Performance:
+0.31%
1Y Performance:
+2.16%
1-Day Range:
$47.45
$48.11
1-Week Range:
$47.42
$50.18
52-Week Range:
$45.80
$60.12
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
47.86 | 121.02B | 48.62B | 6.80B | 7.62B | 2.8038 |
|
LLY
Lilly Eli Co
|
762.73 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
149.79 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
73.77 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.30 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.77 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - FinancialContent
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.
SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com
Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Prurigo Nodularis Market - GlobeNewswire Inc.
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily
Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com
Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com
Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com
CIG’s Market Whiplash: 8.19% YTD Rise, 9.30% Rise in 30 Days - investchronicle.com
Can Navitas Semiconductor Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
LX’s 2023 Market Dance: Up 43.28% – Time to Invest? - investchronicle.com
Terex Corp (TEX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Procore Technologies Inc (PCOR) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Navigating TREE Stock: LendingTree Inc Journey - investchronicle.com
Companhia Siderurgica Nacional ADR (SID) Stock: From Low to High in 52 Weeks - investchronicle.com
The Future of EVgo Inc: Analyzing EVGO - investchronicle.com
Analyzing the Impact of Earnings Reports on Sunstone Hotel Investors Inc Inc. (SHO) Price Performance - investchronicle.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Unilever plc ADR: Rising -3.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
TTWO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Futu Holdings Ltd ADR (FUTU) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Stryker Corp (SYK) Stock: Navigating a Year of Volatility - investchronicle.com
Viking Holdings Ltd’s Banking’s 100-Day Moving Average at 44.43: Will the Stock Break Through? - investchronicle.com
CTRE’s Market Whiplash: 5.78% YTD Rise, 0.22% Rise in 30 Days - investchronicle.com
Sandisk Corp (SNDK) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
LSCC: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Canadian National Railway Co: Navigating Market Fluctuations with a 62.62B Market Cap - investchronicle.com
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):